Loading…
Reirradiation of brain metastases with radiosurgery
Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using...
Saved in:
Published in: | Radiotherapy and oncology 2012-02, Vol.102 (2), p.192-197 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053 |
---|---|
cites | cdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053 |
container_end_page | 197 |
container_issue | 2 |
container_start_page | 192 |
container_title | Radiotherapy and oncology |
container_volume | 102 |
creator | Maranzano, Ernesto Trippa, Fabio Casale, Michelina Costantini, Sara Anselmo, Paola Carletti, Sandro Principi, Massimo Caserta, Claudia Loreti, Fabio Giorgi, Cesare |
description | Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested. |
doi_str_mv | 10.1016/j.radonc.2011.07.018 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920369216</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0167814011003963</els_id><sourcerecordid>920369216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</originalsourceid><addsrcrecordid>eNqFkU1r3DAQhkVpabZp_0EJvvVkd0ay9XEJlNCPQKDQNmcha8eJtl4rleyW_feR2SSHXAoDc3nmHeYZxt4jNAgoP-6a5LZx8g0HxAZUA6hfsA1qZWrQWr1km4KpWmMLJ-xNzjsA4CDUa3bCUWsQWm2Y-EEhlaDg5hCnKg5Vn1yYqj3NLpeiXP0L8221IjEv6YbS4S17Nbgx07uHfsquv3z-dfGtvvr-9fLi01XtW5RzrQx10OlhEIPjXYvcuZa0MH7gEjxCz6Uk0SnXG697id5hB71Gg9wbhE6csg_H3LsU_yyUZ7sP2dM4uonikq0p10jDURayPZI-xZwTDfYuhb1LB4tgV1t2Z4-27GrLgrLFVhk7e1iw9HvaPg096inA-RGgcubfQMlmH2jytA2J_Gy3Mfxvw_MAP4YpeDf-pgPlXVzSVBRatJlbsD_Xj60PQwQQRgpxDyRokMU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920369216</pqid></control><display><type>article</type><title>Reirradiation of brain metastases with radiosurgery</title><source>Elsevier</source><creator>Maranzano, Ernesto ; Trippa, Fabio ; Casale, Michelina ; Costantini, Sara ; Anselmo, Paola ; Carletti, Sandro ; Principi, Massimo ; Caserta, Claudia ; Loreti, Fabio ; Giorgi, Cesare</creator><creatorcontrib>Maranzano, Ernesto ; Trippa, Fabio ; Casale, Michelina ; Costantini, Sara ; Anselmo, Paola ; Carletti, Sandro ; Principi, Massimo ; Caserta, Claudia ; Loreti, Fabio ; Giorgi, Cesare</creatorcontrib><description>Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.</description><identifier>ISSN: 0167-8140</identifier><identifier>EISSN: 1879-0887</identifier><identifier>DOI: 10.1016/j.radonc.2011.07.018</identifier><identifier>PMID: 21880387</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Brain Neoplasms - radiotherapy ; Brain Neoplasms - secondary ; Brain Neoplasms - surgery ; Brain radionecrosis ; Contrast Media ; Dose-Response Relationship, Radiation ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neoplasm Recurrence, Local ; Particle Accelerators ; Proportional Hazards Models ; Radiosurgery ; Radiosurgery - instrumentation ; Radiosurgery - methods ; Radiotherapy Dosage ; Recurrent brain metastases ; Reirradiation ; Retreatment ; Retrospective Studies ; Survival Rate ; Treatment Outcome ; Whole brain radiotherapy</subject><ispartof>Radiotherapy and oncology, 2012-02, Vol.102 (2), p.192-197</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2011 Elsevier Ireland Ltd</rights><rights>Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</citedby><cites>FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21880387$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maranzano, Ernesto</creatorcontrib><creatorcontrib>Trippa, Fabio</creatorcontrib><creatorcontrib>Casale, Michelina</creatorcontrib><creatorcontrib>Costantini, Sara</creatorcontrib><creatorcontrib>Anselmo, Paola</creatorcontrib><creatorcontrib>Carletti, Sandro</creatorcontrib><creatorcontrib>Principi, Massimo</creatorcontrib><creatorcontrib>Caserta, Claudia</creatorcontrib><creatorcontrib>Loreti, Fabio</creatorcontrib><creatorcontrib>Giorgi, Cesare</creatorcontrib><title>Reirradiation of brain metastases with radiosurgery</title><title>Radiotherapy and oncology</title><addtitle>Radiother Oncol</addtitle><description>Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.</description><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - surgery</subject><subject>Brain radionecrosis</subject><subject>Contrast Media</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Particle Accelerators</subject><subject>Proportional Hazards Models</subject><subject>Radiosurgery</subject><subject>Radiosurgery - instrumentation</subject><subject>Radiosurgery - methods</subject><subject>Radiotherapy Dosage</subject><subject>Recurrent brain metastases</subject><subject>Reirradiation</subject><subject>Retreatment</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><subject>Whole brain radiotherapy</subject><issn>0167-8140</issn><issn>1879-0887</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNqFkU1r3DAQhkVpabZp_0EJvvVkd0ay9XEJlNCPQKDQNmcha8eJtl4rleyW_feR2SSHXAoDc3nmHeYZxt4jNAgoP-6a5LZx8g0HxAZUA6hfsA1qZWrQWr1km4KpWmMLJ-xNzjsA4CDUa3bCUWsQWm2Y-EEhlaDg5hCnKg5Vn1yYqj3NLpeiXP0L8221IjEv6YbS4S17Nbgx07uHfsquv3z-dfGtvvr-9fLi01XtW5RzrQx10OlhEIPjXYvcuZa0MH7gEjxCz6Uk0SnXG697id5hB71Gg9wbhE6csg_H3LsU_yyUZ7sP2dM4uonikq0p10jDURayPZI-xZwTDfYuhb1LB4tgV1t2Z4-27GrLgrLFVhk7e1iw9HvaPg096inA-RGgcubfQMlmH2jytA2J_Gy3Mfxvw_MAP4YpeDf-pgPlXVzSVBRatJlbsD_Xj60PQwQQRgpxDyRokMU</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Maranzano, Ernesto</creator><creator>Trippa, Fabio</creator><creator>Casale, Michelina</creator><creator>Costantini, Sara</creator><creator>Anselmo, Paola</creator><creator>Carletti, Sandro</creator><creator>Principi, Massimo</creator><creator>Caserta, Claudia</creator><creator>Loreti, Fabio</creator><creator>Giorgi, Cesare</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>Reirradiation of brain metastases with radiosurgery</title><author>Maranzano, Ernesto ; Trippa, Fabio ; Casale, Michelina ; Costantini, Sara ; Anselmo, Paola ; Carletti, Sandro ; Principi, Massimo ; Caserta, Claudia ; Loreti, Fabio ; Giorgi, Cesare</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - surgery</topic><topic>Brain radionecrosis</topic><topic>Contrast Media</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Particle Accelerators</topic><topic>Proportional Hazards Models</topic><topic>Radiosurgery</topic><topic>Radiosurgery - instrumentation</topic><topic>Radiosurgery - methods</topic><topic>Radiotherapy Dosage</topic><topic>Recurrent brain metastases</topic><topic>Reirradiation</topic><topic>Retreatment</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><topic>Whole brain radiotherapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maranzano, Ernesto</creatorcontrib><creatorcontrib>Trippa, Fabio</creatorcontrib><creatorcontrib>Casale, Michelina</creatorcontrib><creatorcontrib>Costantini, Sara</creatorcontrib><creatorcontrib>Anselmo, Paola</creatorcontrib><creatorcontrib>Carletti, Sandro</creatorcontrib><creatorcontrib>Principi, Massimo</creatorcontrib><creatorcontrib>Caserta, Claudia</creatorcontrib><creatorcontrib>Loreti, Fabio</creatorcontrib><creatorcontrib>Giorgi, Cesare</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Radiotherapy and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maranzano, Ernesto</au><au>Trippa, Fabio</au><au>Casale, Michelina</au><au>Costantini, Sara</au><au>Anselmo, Paola</au><au>Carletti, Sandro</au><au>Principi, Massimo</au><au>Caserta, Claudia</au><au>Loreti, Fabio</au><au>Giorgi, Cesare</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reirradiation of brain metastases with radiosurgery</atitle><jtitle>Radiotherapy and oncology</jtitle><addtitle>Radiother Oncol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>102</volume><issue>2</issue><spage>192</spage><epage>197</epage><pages>192-197</pages><issn>0167-8140</issn><eissn>1879-0887</eissn><abstract>Abstract Purpose To assess the outcome of reirradiation with stereotactic radiosurgery (SRS) of brain metastases (BM) recurring after whole brain radiotherapy (WBRT). Methods and materials Between September 2001 and October 2008, 69 patients who recurred after WBRT were re-irradiated with SRS using a linear accelerator. The dose prescription was generally chosen according to maximum diameter of the tumor as suggested by Radiation Therapy Oncology Group (RTOG) 90-05 protocol. Patients were stratified by Karnofsky Performance Status (KPS), Neurologic Functional Score (NFS), RTOG Recursive Partitioning Analysis (RPA), Score Index for Radiosurgery (SIR), primary disease, dimension and number of BM, and time to first brain recurrence after WBRT. Response, survival, and toxicity were analyzed. Results At time of this retrospective analysis all patients had died. The 69 patients reirradiated with SRS had 150 metastases. Median interval between prior WBRT and SRS was 11 months and median SRS prescribed dose was 20 Gy. Response was obtained in 91% of lesions with 1-year local control rate of 74 ± 4%. Significantly longer duration of response was associated with higher doses (⩾23 Gy) and response achieved after SRS (complete and partial response better than stable disease). Cause of death was brain failure only in 36 (52%) patients. Median overall survival after reirradiation was 10 months. Variables which significantly conditioned survival were KPS and NFS. Four (6%) patients had asymptomatic radionecrosis that developed prevalently when lesion diameters were larger and cumulative doses exceeded the values recommended by RTOG 90-05 protocol. About three-fourth of the patients had a good KPS and NFS after reirradiation. Conclusions Reirradiation of BM with SRS resulted feasible and effective. A correct patient selection and an accurate evaluation of the cumulative irradiation dose were suggested.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>21880387</pmid><doi>10.1016/j.radonc.2011.07.018</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-8140 |
ispartof | Radiotherapy and oncology, 2012-02, Vol.102 (2), p.192-197 |
issn | 0167-8140 1879-0887 |
language | eng |
recordid | cdi_proquest_miscellaneous_920369216 |
source | Elsevier |
subjects | Adult Aged Brain Neoplasms - radiotherapy Brain Neoplasms - secondary Brain Neoplasms - surgery Brain radionecrosis Contrast Media Dose-Response Relationship, Radiation Female Hematology, Oncology and Palliative Medicine Humans Magnetic Resonance Imaging Male Middle Aged Neoplasm Recurrence, Local Particle Accelerators Proportional Hazards Models Radiosurgery Radiosurgery - instrumentation Radiosurgery - methods Radiotherapy Dosage Recurrent brain metastases Reirradiation Retreatment Retrospective Studies Survival Rate Treatment Outcome Whole brain radiotherapy |
title | Reirradiation of brain metastases with radiosurgery |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A28%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reirradiation%20of%20brain%20metastases%20with%20radiosurgery&rft.jtitle=Radiotherapy%20and%20oncology&rft.au=Maranzano,%20Ernesto&rft.date=2012-02-01&rft.volume=102&rft.issue=2&rft.spage=192&rft.epage=197&rft.pages=192-197&rft.issn=0167-8140&rft.eissn=1879-0887&rft_id=info:doi/10.1016/j.radonc.2011.07.018&rft_dat=%3Cproquest_cross%3E920369216%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c416t-79e5058ff3fa25412aa4e839cf260c10b266e357ab9c8b61ca150b81912c91053%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=920369216&rft_id=info:pmid/21880387&rfr_iscdi=true |